Investor Presentaiton

Ambition to lead in RSV across all target populations sanofi Older Adult 60% RSV Market ~€8bn 2030 Infant 30% Toddler 10% Beyfortus Best-in-Class immunization for All Infant Protection in first season RSV Toddler SPO125: First-in-Class vaccine for protection from second season onwards RSV Older Adult SPO256: First-in-Class RSV-hMPV-PIV combination Source: Sanofi internal forecast 22 Vaccines Investor Event

View entire presentation